# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kahn et al.

Art Unit : Unknown

Examiner: Unknown

Serial No.:

: HEREWITH

Title

Filed

: MODULATING THE RAD-NM23 INTERACTION

Commissioner for Patents Washington, D.C. 20231

# PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the specification:

Replace the paragraph beginning at page 1, line 5, with the following rewritten paragraph:

-- This application is a continuation of U.S.N.N. 09/053,967, filed April 2, 1998, which claims priority to U.S. provisional Application No. 60/043,983, filed on April 3, 1997, the contents of which are incorporated herein by reference.--

### In the claims:

Cancel claim 1.

Add claims 2-16.

- A method of modulating an activity of Rad in a cell, comprising modulating the level of nm23 in the cell.
- 3. The method of claim 2, wherein the level of nm23 is modulated by administering an nm23 polypeptide to the cell.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. <u>EL940765871US</u>

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

February 12, 2002

Signature

Typed or Printed Name of Person Signing Certificate

Attorney's Docket No.: 10276-017002 / JDP-031 CN

The stand of the s

Applicant: Kahn et al. Serial No.: 09/053,967 Filed: April 2, 1998

Page : 2

4. The method of claim 2, wherein the level of nm23 is modulated by administering an nm23 polypeptide-encoding nucleic acid to the cell.

- 5. A method for screening for a test compound that modulates the Rad-nm23 interaction, comprising:
  - (a) providing a Rad polypeptide, an nm23 polypeptide, and a test compound; and
- (b) detecting an interaction between the Rad polypeptide and the nm23 polypeptide, wherein a difference in the interaction between the Rad polypeptide and the nm23 polypeptide in the presence of the test compound, compared to in the absence of the test compound, is indicative of a compound that modulates the Rad-nm23 interaction.
- 6. The method of claim 5, wherein the Rad polypeptide or the nm23 polypeptide are provided as a purified polypeptide preparation.
- 7. The method of claim 5, wherein the Rad polypeptide and the nm23 polypeptide are provided as purified polypeptide preparations.
- 8. The method of claim 6 or 7, wherein the Rad polypeptide, nm23 polypeptide, and the test compound are provided in vitro.
- 9. The method of claim 5, wherein the Rad polypeptide or the nm23 polypeptide provided in (a) are expressed in a cell.
- 10. The method of claim 5, wherein the Rad polypeptide and the nm23 polypeptide provided in (a) are expressed in a cell.
- 11. The method of claim 9 or 10, wherein the test compound is contacted with the cell.
- 12. The method of claim 5, wherein detecting the interaction between the Rad polypeptide and the nm23 polypeptide comprises detecting binding of Rad to nm23.
- 13. The method of claim 5, wherein detecting the interaction between the Rad polypeptide and the nm23 polypeptide comprises detecting a modification of Rad or nm23.

Applicant: Kahn et al. Attorney's Docket No.: 10276-017002 / JDP-031 CN

Serial No.: 09/053,967 Filed: April 2, 1998

Page: 3

14. The method of claim 13, wherein the modification is phosphorylation of nm23.

15. The method of claim 5, further comprising (c) administering the compound to an animal and optionally (d) evaluating the in vivo effect of the compound on the animal.

16. The method of claim 15, wherein evaluating the in vivo effect of the compound comprises evaluating cell growth in the animal. --

Applicant: Kahn et al. Attorney's Docket No.: 10276-017002 / JDP-031 CN

Serial No.: 09/053,967 Filed: April 2, 1998

Page : 4

#### **REMARKS**

This amendment is being filed together with a continuation application.

The specification has been amended to insert a reference to the parent application.

Claim 1 has been canceled and new claims 2-16 have been added. The claims are supported throughout the application, e.g., at page 1, line 29 to page 2, line 3; and page 5, line 16 to page 6, line 19.

Attached is a marked-up version of the changes being made by the current amendment. Applicant asks that all claims be examined.

Respectfully submitted,

La Liurines, Reg. No. P-50,635

Date: Feb. 12, 2002

For: Louis Myers Reg. No. 35,965

Fish & Richardson P.C. 225 Franklin Street Boston, Massachusetts 02110-2804

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20388628.doc

Applicant: Kahn et al. Attorney's Docket No.: 10276-017002 / JDP-031 CN

Serial No.: 09/053,967 Filed: April 2, 1998

Page: 5

# Version with markings to show changes made

## In the specification:

Paragraph beginning at page 1, line 5 has been amended as follows:

This application is a continuation of U.S.N.N. 09/053,967, filed April 2, 1998, which claims priority to U.S. provisional Application No. 60/043,983, filed on April 3, 1997, the contents of which are incorporated herein by reference.